Hair LossNCT07556016
Evaluation of the Performance of a Nutricosmetic on Hair & Scalp in Women and Men After 3 and 6 Months
A study testing Active nutricosmetic in people with Hair Loss, run by L'Oreal at 4 sites in France.
Trial summary
In order to validate the product performance, L'Oréal R\&I decided to conduct a new clinical study. The final product is intended to be performant in men and women. Therefore, L'Oréal R\&I wanted to conduct the clinical study on both these populations and compare the efficacy of the product to a placebo. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Hair Loss
- What is being tested?
- Active nutricosmetic
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 239 participants
- Where
- 4 sitesFrance
- Study dates
- 4 Nov 2025to 31 Jul 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy subject and good general health
- Man and woman
- Between 18 and 65 years
- Phototype II to IV (Fitzpatrick Classification scale)
- BMI between 18.5 and 29.9
- With dark brown or black hair at the root
Show all 23Show fewer
- Subject agreeing to take the given Nutricosmetic: 2 capsules per day during 6 months and not introduce new nutritional supplement during the study.
- Subject agreeing to not change sport activities (type and frequency of activities) throughout the entire course of the study
- Subject agreeing to a stable diet with no change of dietary habits, e.g. no start a fasting cure throughout the entire course of the study
- Subject agreeing to keep the same hair dyeing and frequency (if dyeing) during the whole study and at least from the previous month of starting.
- Subject agreeing to keep the same shampoo frequency during all the whole study.
- Subject with a stade IIIv or IV on the Hamilton scale amended by Norwood for men and with a grade I on the Ludwig scale for women.
- Proportion of hair in telogen phase ≥ 20% for the men and ≥ 15% for the women.
- Subject with a total hair density ≥ 150 hair/cm² on test area.
- Subject agreeing to have one shaved zone of 1.2 x 1.5cm on the vertex area at each visit and during the whole study.
- Subject accepting to have hair lock of about 135 hairs cut on D0 and M6
- Subject with a minimum hair length of 6 cm on the vertex and accepting to keep this minimum length during the study.
- Having given freely and expressly his/her informed consent.
- Psychologically able to understand the study related information and to give a written informed consent.
- Affiliated to a health social security system.
- Female of childbearing potential must use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study and during all the study.
- Female subjects of childbearing potential must have a negative pregnancy test at the inclusion.
- Subject agreeing to no increase his/her cigarette and alcohol consumption during the study
Who cannot join
- Pregnant or nursing woman or planning a pregnancy during the study.
- Subject with white or blond hair (coloured white hair also excluded to avoid affecting the PTG count);
- Subject wearing a wig.
- Subject with frizzy hair.
- Subject having performed a hair bleaching or perm in the last 6 months or planned during the study.
- Subject with modification of weight more than 5kg in the 2 months preceding the study and during the study, not using weight loss program or medication.
Show all 38Show fewer
- Subject having performed a visit to sauna or hammam in the 2 weeks preceding the study
- Subject having wounds, moles, tattoos, scars, irritated skin… in the test areas that could influence the study.
- Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.
- Major subject who is under guardianship or who is not able to express his/her consent.
- Subject in a social or sanitary establishment.
- Subject suspected to be non-compliant according to the investigator's judgment.
- France only: Subject having received 6000 euros indemnities for participation in clinical research in the 12 previous months, including participation in the present study.
- Subject enrolled in another clinical trial or which exclusion period is not over.
- Intensive exposure to sunlight or UV-rays 1 month before the study or planned during the study.
- Subject employed at the study site.
- Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk.
- Subject suffering from a severe or progressive disease (AIDS, HIV-positive, infection hepatitis, insulin dependent diabetes mellitus, epilepsy, chronic gastrointestinal disease…) or any other pathology that may interfere with the evaluation of the study results and/or subject safety at the investigator appreciation.
- Subject having history of severe allergy or anaphylactic shock.
- Subject having history of diabetes (type I or type II)
- Subject having antecedent of cancer.
- Subject with known hypersensitivity or allergy to one of the components of the products.
- Subject with known history of or suffering from autoimmune disease and/or immune deficiency.
- Subject having had surgery under general anaesthesia in the month preceding the start of the study.
- Dermatological scalp disorders (ex: psoriasis, scalp dermatitis including seborrheic dermatitis, eczema, pre-cancerous or cancerous lesions, alopecia areata, fungal or bacterial infection, ringworm, lice or flea infestation) or poor hygiene.
- Subject having skin disease on the head that requires actual topical medication or systemic drugs
- Suffering from alopecia of special origins: chimiotherapy-induced (intoxication, drugs), or result from a chronic disease (genetic, endocrinological (excluding androgenetic alopecia)), immunological deficiencies…), result from injury or skin damage, alopecia of infectious origin (mycosis…), cicatricial alopecia, psychological disorders (trichotillomania, trichokryptomania).
- Subject using minoxidil, finosteride, or other anti-hair loss treatment (including local hormonal treatment) within the past 6 months and during the study.
- All other medical treatment (topic or per os) likely to interfere on hair growth or hair loss during the last 6 months prior the screening visit (including prostaglandins, rubefacients agents, all vasodilators, anti-androgens, all local hormonal treatment, silica, silicon, etc…);
- Subject using anti-androgenic medications or drugs causing hypertrichosis (ex: phenytoin, acetazolamide, cyclosporine, diazoxide, psoralens, penicillamine, streptomycin, prostaglandins, vasodilatators and cortisone) or hypotrichosis (ex: anti-coagulants, retinoids, lithium and beta blockers) within the past 6 months and during the study.
- Subject following a long period (>30 days) treatment of anti-inflammatory during the last 4 months before the start of the study (screening)
- Subject using any product having an action on hair loss, an anti-dandruff effect, fortifying effect or an effect on hair weakness within the 2 weeks before the study and during the study (shampoo, conditioner, leave on product applied by friction). Styling products (gel, hairspray, etc) are allowed during the study except on visit days with phototrichogram measurements.
- Subject taking food supplements (including vitamins and minerals) or other active compounds which may have an effect on hair, scalp, skin, nail, … 2 months prior to the start of the study and throughout the entire course of the study
- Subject having had hair implants, surgical intervention or aesthetic procedure for capillary correction or intending to have recourse to this surgery during the study.
- Subject with application of a treatment (oral or topical) with tretinoin or isotretinoin or corticosteroid 8 weeks prior to the start of the study and/or throughout the entire course of the study
- Subject with systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) throughout the entire course of the study
- Subject with systemic long-term therapy with anti-phlogistic agents or analgesics (e.g. diclophenac), except for minor pain relief medicine like acetylsalicylic acid or paracetamol within the last 3 days prior to the start of the study
- Subjects using antibiotic medication within the 2 weeks before the study and during all the study duration
Trial locations and contacts
4 sites in 1 country.
France4 sites
Eurofins Dermscan Pharmascan
Aix-en-Provence, France, 13594
Eurofins EVIC
Bordeaux, France, 33000
Eurofins Spincontrol
Tours, France, 37000
Eurofins Dermscan Pharmascan
Villeurbanne, France, 69100
About this study
In order to validate the product performance, L'Oréal R\&I decided to conduct a new clinical study. The final product is intended to be performant in men and women. Therefore, L'Oréal R\&I wanted to conduct the clinical study on both these populations and compare the efficacy of the product to a placebo.
This clinical study aim is to collect data on Active Nutricosmetic performance and safety, for regulatory purposes. 240 subjects with hair loss, evaluated by phototrichogram (PTG), will be included and will use Active Nutricosmetic or Placebo for 6 months. A follow-up of hair loss (PTG), hair and scalp quality (mass, volume, shininess, fiber quality, sebum rate, diameter), subject satisfaction, illustration and product safety will be done 3 and 6 months after the treatment beginning.
Read the detailed description
Hair loss or alopecia is a common phenomenon that affects more than 80% of men and 50% of women during their lifetime. Alopecia is classified based on the cause and appearance and rarely by gender. Non-scaring (non-cicatricial) and scarring (cicatricial) alopecia are the two types of alopecia described. The non-cicatricial alopecia including Androgenetic alopecia (AGA), telogen effluvium (TE) or alopecia areata (AA) are the types of hair loss in which the hair follicles can typically resume normal activity when inflammatory process subsides. While, in scaring (cicatricial) alopecia the hair loss is irreversible and associated with pathologic conditions. AGA, an androgen-dependent hair loss is the common cause of hair loss and affects about 30-58% of men and approximatively 30% of middle-aged women. Even though alopecia does not often affect humans' global biological health, it has a negative impact on an individual's quality of life.
In order to propose an "in \& out" routine for hair care, L'Oréal R\&I decided to work on a dietary supplement formula for hair loss, hair growth, hair beauty and hair health. R\&I team focused on safety, regulatory compliance and performance to choose the socle of ingredients for this formula. As there were no active ingredient that met all three criteria, L'Oréal R\&I decided to adapt a previous socle of ingredients developed by INNEOV in 2013. As regulation and safety data have evolved between INNEOV was stopped and 2025, L'Oréal R\&I had to adapt the formula. This means that previous clinical data on the formula was not totally relevant and not applicable to the new formula.
The previous formula clinically studied by INNEOV in 2010-2015 was not anymore compliant with regulation, as these regulations have evolved and L'Oréal needs to launch the product on new countries, not taken in account by INNEOV. Moreover, there has been new data on dosage safety for some ingredients, leading to a decrease of dose compared to previous formulas. Some active ingredients were then decreased. As L'Oréal R\&I wanted to keep the efficacy as high as possible, other ingredients that were not present in the previous formulas have been added. These are mainly vitamins and minerals with authorized health claims.
Active nuricosmetic is co-developped in collaboration with dermatologists and nutritionists.
Active ingredients have been selected in order to improve hair and nail health and quality.
Taurine, L-cysteine and OPCs (oligomers of pro-anthocyanidins) of grape seed extract have been chosen to enhance microcirculation, consequently optimizing the supply of nutrients to hair and nail units.
In order to validate the product performance, L'Oréal R\&I decided to conduct a new clinical study. The final product is intended to be performant in men and women. Therefore, L'Oréal R\&I wanted to conduct the clinical study on both these populations and compare the efficacy of the product to a placebo.
This clinical study aim is to collect data on Active Nutricosmetic performance and safety, for regulatory purposes. 240 subjects with hair loss, evaluated by phototrichogram (PTG), will be included and will use Active Nutricosmetic or Placebo for 6 months. A follow-up of hair loss (PTG), hair and scalp quality (mass, volume, shininess, fiber quality, sebum rate, diameter), subject satisfaction, illustration and product safety will be done 3 and 6 months after the treatment beginning.
- Conditions
- Hair Loss
- Being tested
- Active nutricosmetic, Placebo Nutricosmetic
- Medical subject headings
- Alopecia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Active nutricosmeticDietary supplement
Active ingredients have been selected in order to improve hair health and quality.
Taurine, L-cysteine and oligomers of pro-anthocyanidins (OPCs) of grape seed extract have been chosen to enhance microcirculation, consequently optimizing the supply of nutrients to hair and nail units.
Active Nutricosmetic is expected to provide beneficial effects on hair, such as hair growth, lower hair loss, shinier hair, stronger hair, increase of hair density.
Placebo NutricosmeticDietary supplement
Placebo
| Study group | Role | What they receive |
|---|---|---|
| Men in Active Nutricosmetic group | Experimental | Minimum 60 men in Active Nutricosmetic group Receives: Dietary Supplement: Active nutricosmetic |
| men in Placebo Nutricosmetic group | Placebo comparator | Minimum 60 men in Placebo Nutricosmetic group Receives: Dietary Supplement: Placebo Nutricosmetic |
| women in Active Nutricosmetic group | Experimental | Minimum 60 women in Active Nutricosmetic group Receives: Dietary Supplement: Active nutricosmetic |
| women in Placebo Nutricosmetic group | Placebo comparator | Minimum 60 women in Placebo Nutricosmetic group Receives: Dietary Supplement: Placebo Nutricosmetic |
What is being measured
The primary outcome is the main question the study is designed to answer.
total hair density on global population
Change from baseline between Active and Placebo Nutricosmetic groups (global population) in the total hair density (DE), evaluated by phototrichogram (PTG) method at Month6 (6 months of use).
Measured: Month 6 / Day 0
Secondary outcomes (22)
total hair density
Change from baseline between Active and Placebo Nutricosmetic groups in the total hair density (DE), evaluated by phototrichogram (PTG) method at Month 3 (3 months of use).
Measured: Month 3, Day 0
total hair density on men and women population
Change from baseline between Active and Placebo Nutricosmetic groups in the total hair density (DE), evaluated by phototrichogram (PTG) method (in men and in women) at Month 6 (6 months of use).
Measured: Month 6 / Day 0
PTG parameter : telogen hair
Change from baseline between Active and Placebo Nutricosmetic groups of the following PTG parameter at Month 3 and Month 6: percentage of telogen hair (%T)
Measured: Month 6 / Month 3 / Day 0
PTG parameter : anagen hair density
Change from baseline between Active and Placebo Nutricosmetic groups of the following PTG parameter at Month 3 and Month 6: anagen hair density (DA)
Measured: Month 6 / Month 3 / Day 0
PTG parameter : telogen hair density
Change from baseline between Active and Placebo Nutricosmetic groups of the following PTG parameter at Month 3 and Month 6: telogen hair density (DT)
Measured: Month 6 / Month 3 / Day 0
PTG parameter : anagen to telogen ratio (DA/DT)
Change from baseline between Active and Placebo Nutricosmetic groups of the following PTG parameter at Month 3 and Month 6: anagen to telogen ratio (DA/DT)
Measured: Month 6 / Month 3 / Day 0
PTG parameter : hair diameter
Change from baseline between Active and Placebo Nutricosmetic groups of the following PTG parameter at Month 3 and Month 6: hair diameter
Measured: Month 6 / Month 3 / Day 0
Clinical score : hair mass
Change from baseline between Active and Placebo Nutricosmetic groups of the following clinical scored parameters at Month 3 and Month 6: hair mass scored by expert grader using a 10-point scale.
Measured: Month 6 / Month 3 / Day 0
Clinical score : hair volume
Change from baseline between Active and Placebo Nutricosmetic groups of the following clinical scored parameters at Month 3 and Month 6: hair volume ascored by expert grader using a 10-point scale.
Measured: Month 6 / Month 3 / Day 0
Clinical score : hair shine
Change from baseline between Active and Placebo Nutricosmetic groups of the following clinical scored parameters at Month 3 and Month 6: hair shine scored by expert grader using a 10-point scale.
Measured: Month 6 / Month 3 / Day 0
Scalp sebum rate
Change from baseline between Active and Placebo Nutricosmetic groups of scalp sebum rate, measured with Sebumeter® at M3 and M6
Measured: Month 6 / Month 3 / Day 0
Hair sampling : flexion
Change from baseline between Active and Placebo Nutricosmetic groups of the following parameters at Minth 6 measured on hair sampling: flexion
Measured: Month 6 / Day 0
Hair sampling : friction
Change from baseline between Active and Placebo Nutricosmetic groups of the following parameters at Month 6 measured on hair sampling: friction
Measured: Month 6 / Day 0
Hair sampling : traction
Change from baseline between Active and Placebo Nutricosmetic groups of the following parameters at Month 6 measured on hair sampling: traction
Measured: Month 6 / Day 0
Hair sampling : breakage
Change from baseline between Active and Placebo Nutricosmetic groups of the following parameters at M6 measured on hair sampling: breakage
Measured: Month 6 / Day 0
Scalp Reader: hair diameter
Change from baseline between Active and Placebo Nutricosmetic groups of the following parameters at Month 3 and Month 6 measured by Scalp reader: hair diameter in um
Measured: Month 6 / Month 3 / Day 0
Scalp Reader: hair follicle miniaturization
Change from baseline between Active and Placebo Nutricosmetic groups of the following parameters at Month 3 and Month 6 measured by Scalp reader: hair follicle miniaturization from 0 to 100%
Measured: Month 6 / Month 3 / Day 0
Scalp Reader: hair density
Change from baseline between Active and Placebo Nutricosmetic groups of the following parameters at Month 3 and Month 6 measured by Scalp reader: hair density from 0 to 100
Measured: Month 6 / Month 3 / Day 0
Scalp Reader : scalp microbiome indicator
Change from baseline between Active and Placebo Nutricosmetic groups of the following parameters at Month 3 and Month 6 measured by Scalp reader: scalp microbiome indicator.
Measured: Month 6 / Month 3 / Day 0
Hair microbiome
Description on Active and Placebo Nutricosmetic groups at Day 0 and Month 6 of scalp microbiome (scalp swabbing): sequencing and species quantifications
Measured: Month 6 / Day 0
Subject satisfaction
Evaluation of the subject satisfaction using a subjective evaluation questionnaire completed by the subjects at Month 3 and Month 6. Answers will be compared within groups and between active and placebo nutricosmetic groups.
Measured: Month 6 / Month 3
Tolerance
Collection of adverse events (AE) and concomitant treatments throughout the study and global tolerance interpretation
Measured: Month 6 / Month 3 / Day 0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2026
- Study start4 Nov 2025
- Primary completion31 Jul 2026 (estimated)
- Study completion31 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hair LossStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 239 participants (actual)
Sponsor and investigators
- Lead sponsor
- L'Oreal
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07556016
- Sponsor's protocol ID
- 25-1200-U5 / VCY25-008
- Status last verified
- Apr 2026
- First submitted
- 14 Apr 2026
- Last updated
- 29 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Performance of a Nutricosmetic on Hair & Scalp in Women and Men After 3 and 6 Months
- ClinicalTrials.gov ID
- NCT07556016
- Acronym / sponsor ID
- 25-1200-U5 / VCY25-008
- Conditions
- Hair Loss
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 239 participants (actual)
- Lead sponsor
- L'OrealIndustry (pharma, biotech, devices)
- Study start
- 4 Nov 2025 (actual)
- Primary completion
- 31 Jul 2026 (estimated)
- Study completion
- 31 Jul 2026 (estimated)
- First posted
- 29 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In order to validate the product performance, L'Oréal R\&I decided to conduct a new clinical study. The final product is intended to be performant in men and women. Therefore, L'Oréal R\&I wanted to conduct the clinical study on both these populations and compare the efficacy of the product to a placebo.
This clinical study aim is to collect data on Active Nutricosmetic performance and safety, for regulatory purposes. 240 subjects with hair loss, evaluated by phototrichogram (PTG), will be included and will use Active Nutricosmetic or Placebo for 6 months. A follow-up of hair loss (PTG), hair and scalp quality (mass, volume, shininess, fiber quality, sebum rate, diameter), subject satisfaction, illustration and product safety will be done 3 and 6 months after the treatment beginning.
Detailed description
Hair loss or alopecia is a common phenomenon that affects more than 80% of men and 50% of women during their lifetime. Alopecia is classified based on the cause and appearance and rarely by gender. Non-scaring (non-cicatricial) and scarring (cicatricial) alopecia are the two types of alopecia described. The non-cicatricial alopecia including Androgenetic alopecia (AGA), telogen effluvium (TE) or alopecia areata (AA) are the types of hair loss in which the hair follicles can typically resume normal activity when inflammatory process subsides. While, in scaring (cicatricial) alopecia the hair loss is irreversible and associated with pathologic conditions. AGA, an androgen-dependent hair loss is the common cause of hair loss and affects about 30-58% of men and approximatively 30% of middle-aged women. Even though alopecia does not often affect humans' global biological health, it has a negative impact on an individual's quality of life.
In order to propose an "in \& out" routine for hair care, L'Oréal R\&I decided to work on a dietary supplement formula for hair loss, hair growth, hair beauty and hair health. R\&I team focused on safety, regulatory compliance and performance to choose the socle of ingredients for this formula. As there were no active ingredient that met all three criteria, L'Oréal R\&I decided to adapt a previous socle of ingredients developed by INNEOV in 2013. As regulation and safety data have evolved between INNEOV was stopped and 2025, L'Oréal R\&I had to adapt the formula. This means that previous clinical data on the formula was not totally relevant and not applicable to the new formula.
The previous formula clinically studied by INNEOV in 2010-2015 was not anymore compliant with regulation, as these regulations have evolved and L'Oréal needs to launch the product on new countries, not taken in account by INNEOV. Moreover, there has been new data on dosage safety for some ingredients, leading to a decrease of dose compared to previous formulas. Some active ingredients were then decreased. As L'Oréal R\&I wanted to keep the efficacy as high as possible, other ingredients that were not present in the previous formulas have been added. These are mainly vitamins and minerals with authorized health claims.
Active nuricosmetic is co-developped in collaboration with dermatologists and nutritionists.
Active ingredients have been selected in order to improve hair and nail health and quality.
Taurine, L-cysteine and OPCs (oligomers of pro-anthocyanidins) of grape seed extract have been chosen to enhance microcirculation, consequently optimizing the supply of nutrients to hair and nail units.
In order to validate the product performance, L'Oréal R\&I decided to conduct a new clinical study. The final product is intended to be performant in men and women. Therefore, L'Oréal R\&I wanted to conduct the clinical study on both these populations and compare the efficacy of the product to a placebo.
This clinical study aim is to collect data on Active Nutricosmetic performance and safety, for regulatory purposes. 240 subjects with hair loss, evaluated by phototrichogram (PTG), will be included and will use Active Nutricosmetic or Placebo for 6 months. A follow-up of hair loss (PTG), hair and scalp quality (mass, volume, shininess, fiber quality, sebum rate, diameter), subject satisfaction, illustration and product safety will be done 3 and 6 months after the treatment beginning.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Men in Active Nutricosmetic group | Experimental | Dietary Supplement: Active nutricosmeticMinimum 60 men in Active Nutricosmetic group |
| men in Placebo Nutricosmetic group | Placebo comparator | Dietary Supplement: Placebo NutricosmeticMinimum 60 men in Placebo Nutricosmetic group |
| women in Active Nutricosmetic group | Experimental | Dietary Supplement: Active nutricosmeticMinimum 60 women in Active Nutricosmetic group |
| women in Placebo Nutricosmetic group | Placebo comparator | Dietary Supplement: Placebo NutricosmeticMinimum 60 women in Placebo Nutricosmetic group |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (23 listed)
- Healthy subject and good general health
- Man and woman
- Between 18 and 65 years
- Phototype II to IV (Fitzpatrick Classification scale)
- BMI between 18.5 and 29.9
Key exclusion criteria (38 listed)
- Pregnant or nursing woman or planning a pregnancy during the study.
- Subject with white or blond hair (coloured white hair also excluded to avoid affecting the PTG count);
- Subject wearing a wig.
- Subject with frizzy hair.
- Subject having performed a hair bleaching or perm in the last 6 months or planned during the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Active nutricosmeticActive ingredients have been selected in order to improve hair health and quality. Taurine, L-cysteine and oligomers of pro-anthocyanidins (OPCs) of grape seed extract have been chosen to enhance microcirculation, consequently optimizing the supply of nutrients to hair and nail units. Active Nutricosmetic is expected to provide beneficial effects on hair, such as hair growth, lower hair loss, shinier hair, stronger hair, increase of hair density. | Dietary supplement | Men in Active Nutricosmetic group, women in Active Nutricosmetic group |
| Placebo NutricosmeticPlacebo | Dietary supplement | men in Placebo Nutricosmetic group, women in Placebo Nutricosmetic group |
Primary outcome
total hair density on global population
Time frame: Month 6 / Day 0
Change from baseline between Active and Placebo Nutricosmetic groups (global population) in the total hair density (DE), evaluated by phototrichogram (PTG) method at Month6 (6 months of use).
22 secondary outcomes
total hair density
Time frame: Month 3, Day 0
total hair density on men and women population
Time frame: Month 6 / Day 0
PTG parameter : telogen hair
Time frame: Month 6 / Month 3 / Day 0
PTG parameter : anagen hair density
Time frame: Month 6 / Month 3 / Day 0
PTG parameter : telogen hair density
Time frame: Month 6 / Month 3 / Day 0
PTG parameter : anagen to telogen ratio (DA/DT)
Time frame: Month 6 / Month 3 / Day 0
PTG parameter : hair diameter
Time frame: Month 6 / Month 3 / Day 0
Clinical score : hair mass
Time frame: Month 6 / Month 3 / Day 0
Clinical score : hair volume
Time frame: Month 6 / Month 3 / Day 0
Clinical score : hair shine
Time frame: Month 6 / Month 3 / Day 0
Scalp sebum rate
Time frame: Month 6 / Month 3 / Day 0
Hair sampling : flexion
Time frame: Month 6 / Day 0
Hair sampling : friction
Time frame: Month 6 / Day 0
Hair sampling : traction
Time frame: Month 6 / Day 0
Hair sampling : breakage
Time frame: Month 6 / Day 0
Scalp Reader: hair diameter
Time frame: Month 6 / Month 3 / Day 0
Scalp Reader: hair follicle miniaturization
Time frame: Month 6 / Month 3 / Day 0
Scalp Reader: hair density
Time frame: Month 6 / Month 3 / Day 0
Scalp Reader : scalp microbiome indicator
Time frame: Month 6 / Month 3 / Day 0
Hair microbiome
Time frame: Month 6 / Day 0
Subject satisfaction
Time frame: Month 6 / Month 3
Tolerance
Time frame: Month 6 / Month 3 / Day 0
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Hair Loss
Active, not recruitingPhase 3
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
Severe Alopecia Areata
RecruitingPhase 2
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
Active, not recruitingObservational study
Litfulo Capsules Special Investigation
Alopecia Areata
Active, not recruitingObservational study
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data
Alopecia Areata
Active, not recruitingObservational study
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
Alopecia Areata
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Active nutricosmetic in people with Hair Loss, run by L'Oreal at 4 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 23 inclusion and 38 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
total hair density on global population (time frame: Month 6 / Day 0). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.